Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Gains from Investment Securities for 13 consecutive years, with $28000.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Investment Securities rose 1300.0% year-over-year to $28000.0; the TTM value through Mar 2026 reached $21000.0, down 99.95%, while the annual FY2025 figure was -$5000.0, 100.01% down from the prior year.
  • Gains from Investment Securities hit $28000.0 in Q1 2026 for Agios Pharmaceuticals, down from $299000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $43.0 million in Q4 2024 and bottomed at -$306000.0 in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $3.3 million, with a median of $28000.0 recorded in 2026.
  • Year-over-year, Gains from Investment Securities tumbled 1363.16% in 2023 and then surged 13946.41% in 2024.
  • Agios Pharmaceuticals' Gains from Investment Securities stood at $77000.0 in 2022, then soared by 297.4% to $306000.0 in 2023, then soared by 13946.41% to $43.0 million in 2024, then plummeted by 99.3% to $299000.0 in 2025, then tumbled by 90.64% to $28000.0 in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $28000.0, $299000.0, and -$306000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.